PharmaceuticalNews

Lilly's Zepbound Breaks Ground with First U.S. Drug Approval for Sleep Apnea

3 days ago

In a groundbreaking development for the treatment of sleep apnea, Eli Lilly and Company has secured its first drug approval with Zepbound, marking a significant milestone in the pharmaceutical landscape for addressing this common sleep disorder. This approval not only opens doors for more effective interventions but also raises hopes for millions suffering from the condition across the United States.

Lilly's Weight Loss Drug Gains Traction After Novo Nordisk's Clinical Trial Setback

3 days ago

In a significant turn of events, shares of Eli Lilly surged following news that competitor Novo Nordisk faced challenges in its clinical trials for a key weight loss drug. This development highlights a growing advantage for Lilly in the realm of obesity treatments, potentially reshaping the competitive landscape of the pharmaceutical industry.

Keros Therapeutics Faces Setback as Lung Drug Trial Dosing is Halted

11 days ago

In a significant blow to Keros Therapeutics, the company announced a temporary halt in dosing during a clinical trial for its experimental lung drug. This decision comes after preliminary safety concerns arose, leading to a rapid decline in the company’s stock value.

Elimination of Shares: Lilly Announces $15 Billion Buyback and Dividend Increase

14 days ago

In a significant move signaling confidence in its financial health, pharmaceutical giant Eli Lilly & Co. has approved a monumental share buyback program valued at $15 billion. This strategic decision is set to bolster the company’s stock value and offers a promising outlook for shareholders. Simultaneously, Lilly has announced an increase in its quarterly dividend, marking a proactive step in delivering returns to its investors amidst a competitive market environment.

Roche Faces Scrutiny Following Patient Death in Alzheimer's Clinical Trial

2 months ago

Roche Holding AG has come under intense scrutiny following the unfortunate death of a patient during its early-stage clinical trial for an experimental Alzheimer’s drug. The incident has raised concerns not only about the safety of the drug under investigation but also about the broader implications for ongoing Alzheimer's research.

Potential Blockbuster Drug from GSK Shows Promise in Treating Common Nasal Disease

2 months ago

In a significant development for the pharmaceutical industry, GlaxoSmithKline (GSK) has announced that its latest investigational drug could play a pivotal role in treating a prevalent nasal condition known as chronic rhinosinusitis with nasal polyps (CRSwNP). This finding has the potential to transform treatment options for millions who suffer from this disorder, which is characterized by inflammation and swelling of the nasal passages.